That ressource is reserved for health professionals

This space contains information on medical devices, the use of which is reserved for healthcare professionals. In application of the law of December 29, 2011 relating to the strengthening of health security, I certify that I am a health professional and therefore be authorized to access this information.


I am a healthcare professional


Validate


Close window if you are not a healthcare professional

 

Close menu

Contact

About

References

Peer reviewed publications using Promise Proteomics solutions

Many of our customers and collaborators have used our Stable Isotope Labelled (SIL) proteins and monoclonal antibodies (mAbs) in their research work. The topics range from oncology and neurology to cardiology.
We share a selection of published papers with our SIL proteins and SIL mAbs.

2024
2023

  • Development of a candidate reference measurement procedure by ID-LC-MS/MS for total tau protein measurement in cerebrospinal fluid (CSF) – Clinical Chemistry and Laboratory Medicine, 61(7), 1235‑1244

  • IP-LC-MSMS Enables Identification of Three Tau O-GlcNAcylation Sites as O-GlcNAcase Inhibition Pharmacodynamic Readout in Transgenic Mice Overexpressing Human Tau – Journal of Proteome Research, 22(4), 1309‑1321

  • Apolipoprotein E O-glycosylation is associated with amyloid plaques and APOE genotype – Analytical Biochemistry, 672, 115156

  • Absolute quantification of synuclein proteoforms in plasma in patients with Synucleinopathies by LC-MRM mass spectrometry – medRxiv (Cold Spring Harbor Laboratory)

  • Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor – Circulation, 148(2), 144‑158

  • Optimization of a Quantitative Anti-Drug Antibodies against Infliximab Assay with the Liquid Chromatography-Tandem Mass Spectrometry: A Method Validation Study and Future Perspectives – Pharmaceutics, 15(5), 1477

  • Development of an ID-LC–MS/MS method using targeted proteomics for quantifying cardiac troponin I in human serum – Clinical Proteomics, 20(1)

  • Global Discovery and Temporal Changes of Human Albumin Modifications by Pan-Protein Adductomics: Initial Application to Air Pollution Exposure – Journal of the American Society for Mass Spectrometry, 34(4), 595‑607

2022

  • Quantitation of thrombin-activatable fibrinolysis inhibitor in human plasma by isotope dilution mass spectrometry – Analytical Biochemistry, 2022

  • Candidate High-Resolution Mass Spectrometry-Based Reference Method for the Quantification of Procalcitonin in Human Serum Using a Characterized Recombinant Protein as a Primary Calibrator – Analytical Chemistry, 94(10), 4146‑4154.. 2022

  • A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer’s disease – Brain Communications, 4(2). 2022

  • Accelerating the Validation of Endogenous On-Target Engagement and <em>In-cellulo</em> Kinetic Assessment for Covalent Inhibitors of KRAS G12C in Early Drug Discovery – bioRxiv. 2022

2021

  • Experimental Medicine Study to Measure Immune Checkpoint Receptors PD‐1 and GITR Turnover Rates In Vivo in Humans – Clinical Pharmacology & ; Therapeutics, 109(6), 1575‑1582. 2021

  • Development of immunoprecipitation – two-dimensional liquid chromatography – mass spectrometry methodology as biomarker read-out to quantify phosphorylated tau in cerebrospinal fluid from Alzheimer disease patients – Journal of Chromatography A, 1651, 462299. 2021

  • A Personalized Mass Spectrometry–Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM) – Clinical Cancer Research, 27(18), 5028‑5037. 2021

  • Mass Spectrometry Provides a Highly Sensitive Noninvasive Means of Sequencing and Tracking M-Protein in the Blood of Multiple Myeloma Patients – Journal of Proteome Research, 20(8), 4176‑4185. 2021

  • A Personalized Mass Spectrometry–Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM) – Clinical Cancer Research, 27(18), 5028‑5037. 2021

2019

  • Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry – Therapeutic Drug Monitoring: April 04, 2019

  • Direct quantitation of therapeutic antibodies for pharmacokinetic studies using immuno-purification and intact mass analysis – Bioanalysis. 2019: Vol 3 No3

  • Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: Infliximab as proof of principle – Journal of Translational Autoimmunity. Volume 1, April 2019, 100004

  • Determination of Cetuximab in Plasma by Liquid Chromatography-High-Resolution Mass Spectrometry Orbitrap With a Stable Labeled 13C,15N-Cetuximab Internal Standard. – Ther Drug Monit. 2019 Aug;41(4):467-475

2018

  • An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors – Nature Scientific Reports. 2018 Sep 25;8(1):14312

  • Simultaneous quantification of adalimumab and infliximab in human plasma by liquid chromatography-tandem mass spectrometry – Therapeutic Drug Monitoring. 2018 Aug;40(4):417-424.

  • Quantification of cardiac troponin I in human plasma by immunoaffinity enrichment and targeted mass spectrometry – Analytical Bioanalytical Chemistry. 2018 Apr;410(11):2805-2813

  • Quantitation of a Therapeutic Antibody in Serum Using Intact Sequential Affinity Capture, Trypsin Digestion, and LC-MS/MS – Analytical Chemistry. 2018 Jan 2;90(1):866-871

  • Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor – Cell. 2018 Jan 25;172(3):578-589.e17.

2017 and prior years

  • Introducing plasma/serum glycodepletion for the targeted proteomics analysis of cytolysis biomarkers – Talanta. 2017 Aug 1; 170:473-480

  • Multiplex and accurate quantification of acute kidney injury biomarker candidates in urine using Protein Standard Absolute Quantification (PSAQ) and targeted proteomics – Talanta. March 2017; 164: Pages 77-84

  • Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods? – Analytical Bioanalytical Chemistry. 2017 Feb;409(5):1195-1205

  • Quantification of active infliximab in human serum with liquid chromatography-tandem mass spectrometry using a tumor necrosis factor alpha -based pre-analytical sample purification and a stable isotopic labeled infliximab bio-similar as internal standard: A target-based, sensitive and cost-effective method – Journal Chromatography A. 2016 Jul 8; 1454:42-8.

  • Absolute and multiplex quantification of antibodies in serum using PSAQ™ standards and LC-MS – MS. Bioanalysis. 2015;7(10):1237-51

  • DIGESTIF: a universal quality standard for the control of bottom-up proteomics experiments – Journal Proteome Research. 2015 Feb 6;14(2):787-803.

  • Quantification of Tau in Cerebrospinal Fluid by Immunoaffinity Enrichment and Tandem Mass Spectrometry – Clinical Chemistry. 2014 Apr;60(4):683-9

  • Quantification of human growth hormone in serum with a labeled protein as an internal standard: essential considerations – Analytical Chemistry. 2014 Jul 1;86(13):6525-32.

  • The Role of Ion Mobility Spectrometry–Mass Spectrometry in the Analysis of Protein Reference Standards – Analytical Chemistry. 2013, 85 (15), pp 7205–7212

  • PSAQ™ standards for accurate MS-based quantification of proteins: from the concept to biomedical applications – J Mass Spectrometry. 2012 Oct;47(10):1353-63.

  • Development of a Protein Standard Absolute Quantification (PSAQ™) assay for the quantification of Staphylococcus aureus enterotoxin A in serum – Journal of Proteomics. 2012 Jun 6;75(10):3041-9.

  • Accurate quantification of cardiovascular biomarkers in serum using Protein Standard Absolute Quantification (PSAQ™) and selected reaction monitoring – Molecular Cellular Proteomics. 2012 Feb;11(2):M111.008235.

  • Production and use of stable isotope-labeled proteins for absolute quantitative proteomics – Methods Molecular Biology. 2011; 753: 93-115

  •